Targeting Ezh2 could overcome docetaxel resistance in prostate cancer cells
Abstract Background Docetaxel was used to treat metastatic CRPC patients. However, Doc resistance in prostate cancer (PCa) hinders its clinical application. Objective To understand the underlying mechanisms by which Doc resistance is developed and to find novel therapeutic target to cure Doc resista...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2019-01-01
|
| Series: | BMC Cancer |
| Online Access: | http://link.springer.com/article/10.1186/s12885-018-5228-2 |